160 related articles for article (PubMed ID: 28454892)
1. DNA damage response activation and cell cycle dysregulation in infiltrative ameloblastomas: A proposed model for ameloblastoma tumor evolution.
Diniz MG; Guimarães BVA; Pereira NB; de Menezes GHF; Gomes CC; Gomez RS
Exp Mol Pathol; 2017 Jun; 102(3):391-395. PubMed ID: 28454892
[No Abstract] [Full Text] [Related]
2. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma.
Pereira NB; Pereira KM; Coura BP; Diniz MG; de Castro WH; Gomes CC; Gomez RS
J Oral Pathol Med; 2016 Nov; 45(10):780-785. PubMed ID: 27084044
[TBL] [Abstract][Full Text] [Related]
3. High frequency of BRAF V600E mutations in ameloblastoma.
Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K
J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844
[TBL] [Abstract][Full Text] [Related]
4. p53 gene status and expression of p53, MDM2, and p14 proteins in ameloblastomas.
Kumamoto H; Izutsu T; Ohki K; Takahashi N; Ooya K
J Oral Pathol Med; 2004 May; 33(5):292-9. PubMed ID: 15078490
[TBL] [Abstract][Full Text] [Related]
5. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours.
Diniz MG; Gomes CC; Guimarães BV; Castro WH; Lacerda JC; Cardoso SV; de Faria PR; Dias FL; Eisenberg AL; Loyola AM; Gomez RS
Tumour Biol; 2015 Jul; 36(7):5649-53. PubMed ID: 25854168
[TBL] [Abstract][Full Text] [Related]
6. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of Periostin expression in the pathogenesis of ameloblastoma.
Kang Y; Liu J; Zhang Y; Sun Y; Wang J; Huang B; Zhong M
Pathol Res Pract; 2018 Dec; 214(12):1959-1965. PubMed ID: 30196986
[TBL] [Abstract][Full Text] [Related]
8. Expression of parathyroid hormone-related protein in ameloblastomas.
Ohtsuru M
Tokai J Exp Clin Med; 2005 Dec; 30(4):233-9. PubMed ID: 16482944
[TBL] [Abstract][Full Text] [Related]
9. Progress towards personalized medicine for ameloblastoma.
Gomes CC; Diniz MG; Gomez RS
J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150
[TBL] [Abstract][Full Text] [Related]
10. Allelic loss of the ING gene family loci is a frequent event in ameloblastoma.
Borkosky SS; Gunduz M; Beder L; Tsujigiwa H; Tamamura R; Gunduz E; Katase N; Rodriguez AP; Sasaki A; Nagai N; Nagatsuka H
Oncol Res; 2010; 18(10):509-18. PubMed ID: 20681410
[TBL] [Abstract][Full Text] [Related]
11. Expression of proteoglycans in two types of ameloblastoma: novel Immunohistochemical findings.
Gómez-Herrera Z; Molina-Frechero N; Damián-Matsumura P; González-González R; Farfán-Morales JE; Bologna-Molina R
J Biol Regul Homeost Agents; 2018; 32(3):479-487. PubMed ID: 29921372
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of MDM2 protein in ameloblastomas as compared to adenomatoid odontogenic tumor.
Krishna A; Kaveri H; Naveen Kumar RK; Kumaraswamy KL; Shylaja S; Murthy S
J Cancer Res Ther; 2012; 8(2):232-7. PubMed ID: 22842367
[TBL] [Abstract][Full Text] [Related]
13. [Correlations of extrocellular matrix metalloproteinase inducer and microvessel density to invasiveness of ameloblastoma].
Jiang LJ; Shao CK; He D; Li WG; Wu XZ; Cai DZ
Ai Zheng; 2008 Dec; 27(12):1263-6. PubMed ID: 19079990
[TBL] [Abstract][Full Text] [Related]
14. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study.
Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J
Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088
[TBL] [Abstract][Full Text] [Related]
15. K-Ras gene status and expression of Ras/mitogen-activated protein kinase (MAPK) signaling molecules in ameloblastomas.
Kumamoto H; Takahashi N; Ooya K
J Oral Pathol Med; 2004 Jul; 33(6):360-7. PubMed ID: 15200485
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity of the PTCH gene in ameloblastoma.
Farias LC; Gomes CC; Brito JA; Galvão CF; Diniz MG; de Castro WH; Bernardes Vde F; De Marco LA; Gomez RS
Hum Pathol; 2012 Aug; 43(8):1229-33. PubMed ID: 22221699
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel molecular characteristics and cellular biological properties in ameloblastoma.
Kondo S; Ota A; Ono T; Karnan S; Wahiduzzaman M; Hyodo T; Lutfur Rahman M; Ito K; Furuhashi A; Hayashi T; Konishi H; Tsuzuki S; Hosokawa Y; Kazaoka Y
Cancer Med; 2020 Apr; 9(8):2904-2917. PubMed ID: 32096304
[TBL] [Abstract][Full Text] [Related]
18. Identification of recurrent SMO and BRAF mutations in ameloblastomas.
Sweeney RT; McClary AC; Myers BR; Biscocho J; Neahring L; Kwei KA; Qu K; Gong X; Ng T; Jones CD; Varma S; Odegaard JI; Sugiyama T; Koyota S; Rubin BP; Troxell ML; Pelham RJ; Zehnder JL; Beachy PA; Pollack JR; West RB
Nat Genet; 2014 Jul; 46(7):722-5. PubMed ID: 24859340
[TBL] [Abstract][Full Text] [Related]
19. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].
Yan XC; Sun LS; Dong ZW; You Z; Dong Q
Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373
[TBL] [Abstract][Full Text] [Related]
20. Ameloblastoma-Clinical, radiological, and therapeutic findings.
Kreppel M; Zöller J
Oral Dis; 2018 Mar; 24(1-2):63-66. PubMed ID: 29480593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
